Drugs / voruciclib
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03547115 | May 2018 → Jul 2024 | acute myeloid leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma, follicular lymphoma +2 | MEI Pharma, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | voruciclib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03547115 ↗ |
| Action | Inhibit | “Voruciclib, an oral cyclin-dependent kinase (CDK) inhibitor targeting CDK9” PMID 39705540 ↗ Feb 2025 |
| Route | Oral | “Voruciclib will be administered orally” NCT03547115 ↗ |
| Target | CDK9 | “Voruciclib, an oral cyclin-dependent kinase (CDK) inhibitor targeting CDK9” PMID 39705540 ↗ Feb 2025 |